The goal of this study was to survey laboratories in Latin America performing BRCA1 and BRCA2 (BRCA1/2) testing using the same questionnaire administered previously to other testing laboratories around the world 1 .The initial study only captured information from two laboratories in the Latin American region.As this region of the world was under-represented, this study aimed to fill in the knowledge gap.A letter of invitation was sent to 12 laboratories directors of known academic centers in the region performing genetic testing.Two additional laboratories were identified, one at the XVII Congress of the Latin American Association of Genetics (ALAG) meeting in Mendoza, Argentina and a second at the 2019 American Society of Human Genetics meeting in Houston, TX, USA.Nine laboratories responded to the invitation (Fig. 1).We reached out to 14 laboratories in 11 countries.These laboratories were chosen as those we were aware of that performed completed in-house clinical grade sequencing of BRCA1 and BRCA2.Complete testing includes DNA isolation, sequencing, data analysis, and sending out clinical grade reports.Of reporting laboratories, there are many similarities across sites.Eight laboratories used one or more next-generation sequencing platforms to identify BRCA1/2 variants whereas one used Sanger Sequencing.All laboratories sequenced all coding regions of BRCA1/2, but the intronic regions interrogated varied from 1-50 bp.Six of the nine laboratories also sequenced 5' and 3'UTRs.The laboratories using NGS all conducted panel testing of which both BRCA1/2 were evaluated.One laboratory included only BRCA1/2 on its panel.In contrast, deletion/duplication analyses were done by seven of the nine laboratories with MLPA being the most commonly utilized method of detection.Per quality-control metrics, all laboratories confirmed any pathogenic/likely pathogenic variants identified, primarily by Sanger sequencing.Five of the nine labs also confirmed variants of uncertain significance.The rate of VUS for BRCA1/2 for the six labs reporting ranged from 1.24 to up to 60% with an average of 17.3% and a median of 9.5%.The average read depth for BRCA1/ BRCA2 by NGS was 1716X with a range of 200-10,000 reads.The minimum read depth for each lab to meet their quality guidelines ranged from 20 to 500 (average of 128).An important function of clinical testing laboratories is how they evaluate variants of uncertain clinical significance.All nine laboratories performed variant classification in-house.Eight of the